

# CGS 15435

Catalog No: tcsc0018435



## Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg



## Specifications

**CAS No:**

95853-92-2

**Formula:**

$C_{20}H_{21}ClN_2O_2$

**Pathway:**

GPCR/G Protein

**Target:**

Prostaglandin Receptor

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

356.85


## Product Description

CGS 15435, a potent thromboxane (**TxA<sub>2</sub>**) synthetase inhibitor with an **IC<sub>50</sub>** of 1 nM, has a selectivity for Tx synthetase 100000-fold greater than that for cyclooxygenase, PGI<sub>2</sub> synthetase and lipoxygenase enzymes.

IC<sub>50</sub> & Target: IC<sub>50</sub>: 1 nM (TxA<sub>2</sub> synthetase), 60 μM (5-Lipoxygenase), 90 μM (PGI<sub>2</sub> synthetase), 1200 μM (Cyclooxygenase)<sup>[1]</sup>

**In Vitro:** CGS 15435 is a highly specific Tx synthetase inhibitor. CGS 15435 is only weakly effective as an inhibitor of PGE<sub>2</sub> (Cyclooxygenase, IC<sub>50</sub>=1200 μM), prostacyclin (PGI<sub>2</sub> synthetase, IC<sub>50</sub>=90 μM) or 5-Lipoxygenase (IC<sub>50</sub>=60 μM) product formation<sup>[1]</sup>.

**In Vivo:** CGS 15435 has a long duration of action, since the increases in the plasma levels of TxB<sub>2</sub> are prevented even at 24 h after CGS 15435 administration. CGS 15435 significantly inhibits TxB<sub>2</sub> formation 4, 6, 12 and 24 h after dosing. Administration of CGS 15435 0.25 or 24 h prior to Arachidonic acid (AA) produced no increase in TxB<sub>2</sub> in the surviving animals (4/4 and 5/6, respectively). The final TxB<sub>2</sub> levels in the CGS15435A (0.25 and 24 h pretreatment) groups are significantly lower (P[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!